ETS-related transcription factor Elf-4 (ELF4) (ELF4)

ETS-related transcription factor Elf-4 (ELF4), also known as Myeloid Elf-1-like factor (MEF), is a member of the ETS family of transcription factors that plays a pivotal role in innate immunity and hematopoiesis [1]. It functions by binding to specific DNA sequences to regulate the transcription of genes involved in the type I interferon response, such as IFN-beta, and cell cycle regulators like p21 and p53 [2][3]. In the context of disease, ELF4 is recognized as a potent oncogene in several types of leukemia and solid tumors, where its overexpression drives aberrant cell proliferation and inhibits apoptosis [4][5]. Conversely, its deficiency has been linked to impaired immune responses and defects in the maintenance of hematopoietic stem cell quiescence [6]. While ELF4 is considered a high-value therapeutic target, particularly for its role in cancer and inflammatory disorders, there are currently no approved small-molecule inhibitors specifically targeting it [7]. Current research efforts focus on utilizing RNA-based therapies, such as antisense oligonucleotides or siRNA, to modulate ELF4 mRNA levels and subsequent protein expression in pathological states [8]. The mRNA itself serves as a direct target for these emerging nucleic acid-based modalities, aiming to silence the oncogenic or pro-inflammatory signaling of the ELF4 protein [9]. Monitoring ELF4 mRNA expression levels is also explored as a potential biomarker for disease progression and treatment response in specific malignancies [10].

Other names

Myeloid Elf-1-like factorMEFE74-like factor 4ELFR

Reduction of target protein expression through mRNA degradation (via siRNA or antisense oligonucleotides) or inhibition of transcriptional activity